Posted by Michael Wonder on 02 Mar 2018
EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders
2 March 2018 - Medicine to be voluntarily withdrawn from the market by the company.
The EMA has started an urgent review of the multiple sclerosis medicine Zinbryta (daclizumab) following 7 cases of serious inflammatory brain disorders in Germany, including encephalitis and meningoencephalitis, and one case in Spain.
In parallel to the start of the review, the company that markets Zinbryta (Biogen) has informed EMA of its intention to voluntarily withdraw the medicine’s marketing authorisations.
